Statement: AJOVY® (fremanezumab-vfrm) injection Access Update

We continue to experience strong demand for AJOVY® (fremanezumab-vfrm) injection since launching in September 2018, as evidenced by market share and utilization. Acceptance by patients and healthcare providers lends an important voice to our ongoing discussions with payers.

Currently, we estimate more than 75 percent of commercial patients have coverage for AJOVY. This includes coverage with two large national PBMs, CVS Caremark, and ESI. Effective April 1, AJOVY moved from non-preferred to preferred on Express Scripts’ National Preferred & Basic Commercial Formularies. Also effective on April 1, AJOVY moved from not covered to preferred on Cigna’s Commercial Standard Formulary. This is good news for patients as it means more lives are covered for this important treatment. Discussions with numerous national and regional payers to provide formulary coverage continue.

Finally, AJOVY will move to non-preferred on Prime’s Accord Commercial Formulary and will be not covered on Prime’s Net Results Commercial Formulary.

We are committed to increasing access to AJOVY, and commercially insured patients – regardless of formulary decisions – may still use the Savings Offer for AJOVY, allowing them to pay as little as $0.  Note that patients eligible for government-sponsored coverage are not eligible for the Savings Offer. Teva’s Shared Solutions® program is also committed to helping patients gain access to AJOVY with a team available to research and understand patients’ coverage and benefits.

We are confident in the value AJOVY brings to the healthcare system, as well as the strategic decisions made when establishing the price for AJOVY.


AJOVY® is indicated for the preventive treatment of migraine in adults.



Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.

Please click here for full Prescribing Information for AJOVY® (fremanezumab-vfrm) injection.


Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding AJOVY, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

  • the uncertainty of commercial success of AJOVY, including our ability to achieve formulary coverage;
  • our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; the uncertainty of commercial success of AUSTEDO®; competition from companies with greater resources and capabilities; efforts of pharmaceutical companies to limit the use of generics, including through legislation and regulations; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our products, both from competing products and increased regulation; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; our ability to take advantage of high-value opportunities; the difficulty and expense of obtaining licenses to proprietary technologies; and the effectiveness of our patents and other measures to protect our intellectual property rights;
  • our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
  • our business and operations in general, including: failure to effectively execute our restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to the ongoing review of our R&D programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets ;
  • compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into selling and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
  • other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2018, including the sections thereof captioned "Risk Factors." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.




IR Contacts

United States

Kevin C. Mannix

(215) 591-8912



Ran Meir

(215) 591-3033





PR Contacts

United States

Doris Saltkill

(913) 777-3343



Yonatan Beker

972 (54) 888 5898